Cost-utility analysis of meaning-centered group psychotherapy for cancer survivors.

Cost-utility analysis of meaning-centered group psychotherapy for cancer survivors.

Psychooncology. 2018 Apr 06;:

Authors: van der Spek N, Jansen F, Holtmaat K, Vos J, Breitbart W, van Uden-Kraan CF, Tollenaar RAEM, Cuijpers P, Coupé VMH, Verdonck-de Leeuw IM

Abstract
BACKGROUND: Meaning-centered group psychotherapy for cancer survivors (MCGP-CS) improves meaning, psychological well-being, and mental adjustment to cancer and reduces psychological distress. This randomized controlled trial was conducted to investigate the cost-utility of MCGP-CS compared to supportive group psychotherapy (SGP) and care-as-usual (CAU).
METHODS: In total, 170 patients were randomized to MCGP-CS, SGP, or CAU. Intervention costs, direct medical and non-medical costs, productivity losses and health-related quality of life were measured until six months follow-up, using the TIC-P, PRODISQ, data from the hospital information system, and the EQ-5D. The cost-utility was calculated by comparing mean cumulative costs and quality adjusted life years (QALYs).
RESULTS: Mean total costs ranged from €4,492 (MCGP-CS) to €5,304 (CAU). Mean QALYs ranged .507 (CAU) to .540 (MCGP-CS). MCGP-CS had a probability of 74% to be both less costly and more effective than CAU, and 49% compared to SGP. Sensitivity analyses showed these findings are robust. If society is willing to pay €0 for one gained QALY, MCGP-CS has a 78% probability of being cost-effective compared to CAU. This increases to 85% and 92% at willingness-to-pay thresholds of €10,000 and €30,000, which are commonly accepted thresholds.
CONCLUSIONS: MCGP-CS is highly likely a cost-effective intervention, meaning that there is a positive balance between the costs and gains of MCGP-CS, in comparison to SGP and CAU.

PMID: 29624807 [PubMed - as supplied by publisher]

https://ift.tt/2ErISeI